Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
Last trade$2.76
Day change+$0.005 (+0.18%)
Day range$2.64 – $2.82
Volume178,617
Market cap$26M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$25.74M
Price / earnings
—
Price / book
0.25×
Price / sales
—
EV / sales
—
EV / EBITDA
0.01×
Profitability
Earnings per share
-$9.72
Return on assets
-70.57%
Return on equity
-88.61%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.01×
Current ratio
6.09×
Quick ratio
6.09×
Cash ratio
1.6×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$80.43M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ACET, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$4.17M
$3.85M
$4.08M
$6.85M
$5.1M
$3.97M
$7.07M
$7.47M
Research and development
$15.63M
$18.45M
$17.49M
$25.04M
$22.85M
$28.42M
$22.81M
$23.27M
Total operating expenses
$19.8M
$22.3M
$21.57M
$31.89M
$27.95M
$32.39M
$29.89M
$30.74M
Operating income
-$19.8M
-$22.3M
-$21.57M
-$31.89M
-$27.95M
-$32.39M
-$29.89M
-$30.74M
Interest expense
-$23K
-$22K
-$23K
-$24K
-$12K
$0
$0
-$1K
Income before taxes
-$18.88M
-$21.22M
-$20.24M
-$30.52M
-$26.86M
-$31.22M
-$28.21M
-$28.73M
Income taxes
$1K
$143K
$0
$0
$0
$0
$0
$0
Net income
-$18.88M
-$21.36M
-$20.24M
-$30.52M
-$26.86M
-$31.22M
-$28.21M
-$28.73M
Net income attributable to common shareholders
-$18.88M
-$21.36M
-$20.24M
-$30.52M
-$26.86M
-$31.22M
-$28.21M
-$28.73M
EBITDA
-$18.76M
-$21.1M
-$20.23M
-$30.41M
-$26.38M
-$30.74M
-$28.21M
-$29.12M
Basic earnings per share
-$1.76
-$1.99
-$1.88
-$2.91
-$4.72
-$5.48
-$4.96
-$5.06
Diluted earnings per share
-$1.76
-$1.99
-$1.88
-$2.91
-$4.72
-$5.48
-$4.96
-$5.06
Recent news
Company coverage with links to the original publishers.
The lupus nephritis drug development pipeline is rapidly expanding with 30+ pharmaceutical companies developing 35+ pipeline therapies across various clinical stages. Key players including Novartis, Simcere Pharmaceutical, Kyverna Therapeutics, Century Therapeutics, and Adicet Bio are advancing promising treatments with novel mechanisms of action such as BAFF-R inhibitors, CAR-NK cell therapies, and anti-CD19/CD20 approaches. Recent regulatory milestones include FDA RMAT designations for cell therapies and positive Phase III trial results, indicating accelerating progress in addressing this serious autoimmune kidney disease.
Johnson & Johnson announced positive Phase 2b results for nipocalimab, an experimental FcRn blocker for treating systemic lupus erythematosus (SLE). The JASMINE study of 228 subjects met its primary endpoint and key secondary endpoints, with a favorable safety profile. The company plans to initiate Phase 3 trials. The lupus treatment market includes competing programs from UCB/Biogen, Cartesian Therapeutics, and Adicet Bio.
ACET ($ACT), a blockchain-powered DeFi platform, has partnered with the Royal Office of H.H. Sheikh Ahmed Bin Faisal Al-Qassimi to drive blockchain adoption and financial innovation in the UAE, including integrating ACET ($ACT) into a $3.9 billion casino resort project.
Acme Worawat, founder of the ACET (ACT) digital currency, has proposed integrating Bitcoin into Thailand's economic framework, including utilizing it as part of the country's reserve fund. The initiative aims to position Thailand as a global leader in Blockchain technology and attract global crypto investments.